Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Betnesol 0.1% eye ointment
1104010D0BBABAB
|
Betnesol (Ear/Eye/Nasal) | Betamethasone sodium phosphate | Eye | No data available |
|
Betnesol 4mg/1ml solution for injection ampoules
0603020C0BBABAA
|
Betnesol (Systemic) | Betamethasone sodium phosphate | Endocrine System | No data available |
|
Betnesol-N eye ointment
1104010D0BBACAD
|
Betnesol (Ear/Eye/Nasal) | Betamethasone sodium phosphate | Eye | No data available |
|
Betnovate rectal ointment
0107020B0BBAAAA
|
Betnovate (Rectal) | Betamethasone | Gastro-Intestinal System | No data available |
|
Betnovate-N ointment
1304000F0BBANCE
|
Betnovate (Topical) | Betamethasone valerate | Skin | No data available |
|
BetterYou D400 Junior Vitamin D 400units Daily oral spray
0906040G0ETABCI
|
BetterYou | Colecalciferol | Nutrition and Blood | No data available |
|
BetterYou D4000 Vitamin D 4,000units Daily oral spray
0906040G0ETAEFM
|
BetterYou | Colecalciferol | Nutrition and Blood | No data available |
|
BetterYou Infant Vitamin D 400units Daily oral spray
0906040G0ETACCI
|
BetterYou | Colecalciferol | Nutrition and Blood | No data available |
|
BetterYou Vitamin D + K2 3000iu D3 + 75ug K2 Daily oral spy
090607000BBMEBP
|
Proprietary compound preparation BNF 0906070 | Other multivitamin preparations | Nutrition and Blood | No data available |
|
Bevacizumab 1.25mg/0.05ml solution for injection vials
0801050APAAACAC
|
Bevacizumab | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevacizumab 100mg/4ml solution for infusion vials
0801050APAAAAAA
|
Bevacizumab | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevacizumab 400mg/16ml solution for infusion vials
0801050APAAABAB
|
Bevacizumab | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevqolva 100mg/4ml concentrate for inf vials
0801050APBJAAAA
|
Bevqolva | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bevqolva 400mg/16ml concentrate for inf vials
0801050APBJABAB
|
Bevqolva | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Bextra 10mg tablets
1001010ALBBAAAA
|
Bextra | Valdecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Bextra 20mg tablets
1001010ALBBABAB
|
Bextra | Valdecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Bextra 40mg tablets
1001010ALBBACAC
|
Bextra | Valdecoxib | Musculoskeletal and Joint Diseases | No data available |
|
Beyfortus 100mg/1ml inj pre-filled syringes
0503050C0BBAAAA
|
Beyfortus | Nirsevimab | Infections | No data available |
|
Beyfortus 50mg/0.5ml inj pre-filled syringes
0503050C0BBABAB
|
Beyfortus | Nirsevimab | Infections | No data available |
|
Bezafibrate 200mg/5ml oral suspension
0212000D0AAACAC
|
Bezafibrate | Bezafibrate | Cardiovascular System | No data available |
|
Bezagen XL 400mg tablets
0212000D0BCAAAB
|
Bezagen | Bezafibrate | Cardiovascular System | No data available |
|
Bi-Aglut gluten free biscuits
0904010A0BSAABF
|
Bi-Aglut (G/F W/F Bisc) | Gluten free/wheat free biscuits | Nutrition and Blood | No data available |
|
Bi-Aglut gluten free cracker toast
0904010A0BSABBF
|
Bi-Aglut (G/F W/F Bisc) | Gluten free/wheat free biscuits | Nutrition and Blood | No data available |
|
Bi-Aglut gluten free crackers
0904010A0BSACBF
|
Bi-Aglut (G/F W/F Bisc) | Gluten free/wheat free biscuits | Nutrition and Blood | No data available |
|
Bi-Aglut gluten free pasta fusilli
0904010Q0BIAAAQ
|
Bi-Aglut (Gluten free pasta) | Gluten free pastas | Nutrition and Blood | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.